Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.

IF 0.9 Q4 RESPIRATORY SYSTEM Lung Cancer Management Pub Date : 2023-03-01 DOI:10.2217/lmt-2022-0014

Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins

{"title":"Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience.","authors":"Christopher Cronin, Shahid Iqbal, Abdul R Farooq, Pauline O'Dea, Louise Burke, Seamus O'Reilly, Deirdre O'Mahony, Derek G Power, Richard M Bambury, Dearbhaile C Collins","doi":"10.2217/lmt-2022-0014","DOIUrl":null,"url":null,"abstract":"Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.Methods: We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.Results: 62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.Conclusion: High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.","PeriodicalId":43551,"journal":{"name":"Lung Cancer Management","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/92/4b/lmt-12-58.PMC10241113.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lung Cancer Management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/lmt-2022-0014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: Adjuvant chemotherapy in NSCLC is associated with modest benefits and significant toxicity. We sought to evaluate the toxicity of adjuvant chemotherapy and disease-specific outcomes in a real-world population.

Methods: We performed a retrospective analysis of patients undergoing adjuvant chemotherapy for NSCLC in an Irish center over a 7-year period. We described treatment-associated toxicity, recurrence-free survival and overall survival.

Results: 62 patients underwent adjuvant chemotherapy. Treatment-associated hospitalisation occurred in 29% of patients. Relapse was recorded in 56% of patients and median recurrence-free survival was 27 months.

Conclusion: High rates of disease recurrence and treatment-associated morbidity were observed in patients receiving adjuvant chemotherapy for NSCLC. Novel therapeutic strategies are required to improve outcomes in this population.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非小细胞肺癌辅助化疗的真实结果和毒性:单中心研究。

目的:非小细胞肺癌的辅助化疗有一定的益处和明显的毒性。我们试图在现实世界的人群中评估辅助化疗的毒性和疾病特异性结果。方法:我们对爱尔兰一家中心7年来接受非小细胞肺癌辅助化疗的患者进行了回顾性分析。我们描述了治疗相关的毒性、无复发生存期和总生存期。结果:62例患者接受了辅助化疗。29%的患者出现治疗相关住院。56%的患者复发，中位无复发生存期为27个月。结论:在接受辅助化疗的非小细胞肺癌患者中，疾病复发率和治疗相关发病率较高。需要新的治疗策略来改善这一人群的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer Management RESPIRATORY SYSTEM-

CiteScore

2.30

自引率

0.00%

发文量